Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease–associated pruritus - 10/03/21
Funding sources: Financial support for this study was received from Cara Therapeutics, Inc. |
|
Conflicts of interest: Drs Munera, Spencer, and Menzaghi are employees of Cara Therapeutics, Inc. Dr Vernon is an employee of Evidera. Dr Ständer discloses consulting fees from Almirall, Beiersdorf, Bellus Health, Cara Therapeutics, Inc, Celgene Corporation, Galderma Laboratorium, Galderma R&D, LEO Pharma, Menlo Therapeutics, Novartis, Sienna Biopharmaceuticals, Trevi Therapeutics, and Vanda Pharmaceuticals, lecture fees from Sanofi, and is an investigator for Dermasence, Kiniksa, Menlo Therapeutics, Novartis, and Trevi Therapeutics. |
|
Fig 1 was presented at the Second Annual Dermatology Drug Development Summit, Boston, MA, November 27-29, 2018. |
|
IRB approval status: Reviewed and approved by the Quorum Review Institutional Review Board. |
|
Reprints not available from the authors. |
Vol 84 - N° 4
P. 1132-1134 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?